Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Zhang, Yi ^a   Chen, Fu Qiang ^a   Sun, Ye Hong ^a   Zhou, Shu Yan ^a   Li, Ti Yuan ^a   Chen, Rui ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 1; MESSENGER RNA; DNA; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 1; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; CELL CYCLE; CELL PROLIFERATION; CPG ISLAND; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UTERINE CERVIX TUMOR; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CPG ISLANDS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; PHENOTYPE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 80054070144     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-98     Document Type: Article

References (19)

1. Discovery of DNA methylation markers in cervical cancer using relaxation ranking. Ongenaert M, Wisman GB, Volders HH, Koning AJ, Zee AG, van Criekinge W, Schuuring E, BMC Med Genomics 2008 1 57 10.1186/1755-8794-1-57 19025626
2. The role of DNA methyltransferase 1 in growth control. Szyf M, Front Biosci 2001 6 599 609 10.2741/szyf 11282571
3. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S, Hirohashi S, Carcinogenesis 2006 27 6 1160 1168 10.1093/carcin/bgi361 16537562 (Pubitemid 43985431)
4. RNA interference-mediated knockdown of DNMT1 and DNMT3B induces CXCL12 expression in MCF-7 breast cancer and AsPC1 pancreatic carcinoma cell lines. Sowinska A, Jagodzinski PP, Cancer letters 2007 255 1 153 159 10.1016/j.canlet.2007.04.004 17532557 (Pubitemid 47212611)
5. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, et al. Nature 2002 416 6880 552 556 10.1038/416552a 11932749 (Pubitemid 34288859)
6. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Robert SM, Beaulieu Normand, Gauthier France, Nature genetics 2002 33 9 61 65 12496760
7. RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF, Minna JD, Cancer research 2004 64 9 3137 3143 10.1158/0008-5472.CAN-03-3046 15126351 (Pubitemid 38581414)
8. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Leu YW, Rahmatpanah F, Shi H, Wei SH, Liu JC, Yan PS, Huang TH, Cancer research 2003 63 19 6110 6115 14559786 (Pubitemid 37255146)
9. CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Ting AH, Jair KW, Suzuki H, Yen RW, Baylin SB, Schuebel KE, Nature genetics 2004 36 6 582 584 10.1038/ng1365 15156141 (Pubitemid 38715984)
10. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Ye C, Shrubsole MJ, Cai Q, Ness R, Grady WM, Smalley W, Cai H, Washington K, Zheng W, Oncology reports 2006 16 2 429 435 16820927
11. PTEN and NDUFB8 aberrations in cervical cancer tissue. Hsieh SM, Maguire DJ, Lintell NA, McCabe M, Griffiths LR, Advances in experimental medicine and biology 2007 599 31 36 10.1007/978-0-387-71764-7-5 17727244
12. Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Qi M, Anderson AE, Chen DZ, Sun S, Auborn KJ, Molecular medicine Cambridge, Mass 2005 11 1-12 59 63 16557333
13. Regulation of DNA methylation on the expression of the FHIT gene contributes to cervical carcinoma cell tumorigenesis. Wu Y, Meng L, Wang H, Xu Q, Wang S, Wu S, Xi L, Zhao Y, Zhou J, Xu G, et al. Oncology reports 2006 16 3 625 629 16865265
14. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, Iwata T, Hirasawa A, Fujii T, Susumu N, et al. International journal of oncology 2007 31 4 713 720 17786301
15. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Cheung HW, Ching YP, Nicholls JM, Ling MT, Wong YC, Hui N, Cheung A, Tsao SW, Wang Q, Yeun PW, et al. Molecular carcinogenesis 2005 43 4 237 245 10.1002/mc.20106 15937956 (Pubitemid 41134431)
16. Promoter methylation of SFRPs gene family in cervical cancer. Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, Chu TY, Lai HC, Lin YW, Gynecologic oncology 2009 112 2 301 306 10.1016/j.ygyno.2008.10.004 19038436
17. Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer. Kitkumthorn N, Yanatatsanajit P, Kiatpongsan S, Phokaew C, Triratanachat S, Trivijitsilp P, Termrungruanglert W, Tresukosol D, Niruthisard S, Mutirangura A, BMC cancer 2006 6 55 10.1186/1471-2407-6-55 16524460
18. Identification of novel DNA methylation markers in cervical cancer. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, et al. International journal of cancer 2008 123 1 161 167 10.1002/ijc.23519 (Pubitemid 351705204)
19. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, Snijders PJ, Journal of the National Cancer Institute 2004 96 4 294 305 10.1093/jnci/djh031 14970278 (Pubitemid 38256274)